CHANGES IN HEART RATE, HEART RATE VARIABILITY AND QT INTERVAL IN WOMEN WITH RHEUMATOID ARTHRITIS DURING RITUXIMAB TREATMENT
https://doi.org/10.14412/1995-4484-2014-270-276
Abstract
Rheumatoid arthritis (RA) is a proven high cardiovascular risk disease. High heart rate (HR), lower heart rate variabil- ity (HRV), and increased QT interval are considered as predictors of cardiovascular events in patients with coronary heart disease, chronic heart failure, and diabetes mellitus. In RA, there is a pronounced rise in HR, a reduction in HRV, and an increase in QT interval mainly due to the factors reflecting the severity of the disease. Rituximab (RTM) is successfully used to treat patients with high RA activity. At the same time there are only a few pieces of evidence for the effect of the drug on the cardiovascular system.
Objective: to study changes in HR, HRV, and QT interval values obtained during electrocardiography (ECG) Holter monitoring (ECG HM) in RTM-treated women during a 6-month follow-up.
Subjects and methods: The investigation enrolled 55 women (mean age 50 years) with a definite diagnosis of RA and its high activity. The patients were examined 6 months after administration of RTM. The latter was infused intra- venously twice (500 and 1000 mg in 22% and 78% of the patients, respectively) during therapy with disease-modifying antirheumatic and non-steroidal anti-inflammatory drugs and glucocorticoids. The RA patients were divided into two groups: 1) a satisfactory/good effect of RTM according to the EULAR criteria (n = 41); 2) no effect (n = 14). Analysis of 24-hour ECG HM yielded the values of HR and mean duration of corrected QT interval (QTc). The tim- ing HRV values obtained at ECG HM were standardized from age and mean HR (SDNNn, RMSSDn, and pNN50n).
Results. The baseline HRmin and HRmean values were higher and SDNNn was lower in the RA patients in Group 1 than those in Group 2 (p < 0.05). In Group 1, RTM therapy was accompanied by a reduction in HRmean and HRmin by 8% and by an increase in SDNNn by 3%, RMSSDn by 26%, and pNN50n by 33% whereas no significant changes in HR and HRV were found in Group 2. The RTM therapy-induced HRmean decrease was associated with the reductions of C-reactive protein concentration and HAQ disability index (p < 0.01), the increases of rMSSDn and pNN50n associated with lower HAQ index, ERS, and DAS28 (p < 0.01). There were no differences in QTc in Groups 1 and 2 during 6 months after RTM therapy. Thus, effective RTM therapy is attended by reduced HR and improved HRV values.
About the Authors
D. S. Novikova
Nasonova Research Institute of Rheumatology, Moscow, Russia
Russian Federation
Russian Federation
T. V. Popkova
Nasonova Research Institute of Rheumatology, Moscow, Russia
Russian Federation
Russian Federation
E. V. Gerasimova
Nasonova Research Institute of Rheumatology, Moscow, Russia
Russian Federation
Russian Federation
A. A. Novikov
Nasonova Research Institute of Rheumatology, Moscow, Russia
Russian Federation
Russian Federation
E. N. Aleksandrova
Nasonova Research Institute of Rheumatology, Moscow, Russia
Russian Federation
Russian Federation
E. L. Nasonov
Nasonova Research Institute of Rheumatology, Moscow, Russia
Russian Federation
Russian Federation
References
1. Насонов ЕЛ, Каратеев ДЕ, Балабанова РМ. Ревматоидный артрит. В кн.: Ревматология. Национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой. Москва: ГЭОТАР- Медиа; 2008. С. 290–331. [Nasonov EL, Karateev DE, Balabanova RM. Rheumatoid arthritis. In: Revmatologiya. Natsional’noe rukovodstvo [Rheumatology. National Guide]. Nasonov EL, Nasonova VA, editors. Moscow: GEOTAR-Media; 2008. P. 290–331.]
2. Фоломеева ОМ, Галушко ЕА, Эрдес ШФ. Распространенность ревматических заболеваний
3. в популяциях взрослого населения России и США. Научно- практическая ревматология. 2008;47(4):4–13. [Folomeeva OM, Galushko EA, Erdes SF. Prevalence of rheumatic diseases in adult populations of Russian Federation and USA. Nauchno-praktich- eskaya revmatologiya = Rheumatology Science and Practice. 2008;47(4):4–13. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2008-529.
4. Галушко ЕА, Эрдес ШФ, Базоркина ДИ и др.Распространенность ревматоидного артрита в России (по данным эпидемиологического исследования). Терапевтический архив. 2010;82(5):9–14. [Galushko EA, Erdes ShF, Bazorkina DI, et al. Prevalence of rheumatoid arthritis in Russia (according to epidemiological research). Terapevticheskii arkhiv. 2010;82(5):9–14. (In Russ.)]
5. Попкова ТВ, Новикова ДС, Насонов ЕЛ. Атеросклероз при ревматических заболеваниях. В кн.: Ревматология: клинические рекомендации. Москва: ГЭОТАР-Медиа; 2010. С. 678–702. [Popkova TV, Novikova DS, Nasonov EL. Atherosclerosis at rheumatic diseases. In: Revmatologiya: klinich- eskie rekomendatsii [Rheumatology: clinical recommendations]. Moscow: GEOTAR-Media; 2010. P. 678–702.]
6. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-
7. based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other types of inflammatory arthritis. Ann Rheum Dis. 2010;69(2):325–31. DOI: 10.1136/ard.2009.113696.
8. Gabriel SE. Why do people with rheumatoid arthritis still die pre- maturely? Ann Rheum Dis. 2008;67 Suppl 3:iii30–4. DOI: 10.1136/ard.2008.098038.
9. Meune C, Touze E, Trinquart L, Allanore Y. High risk of clinical cardiovascular events in RA: levels of associations of myocardial infarction and stroke through a systematic review and meta-analy- sis. Arch Cardiovasc Dis. 2010;103(4):253–61. DOI: 10.1016/j.acvd.2010.03.007.
10. Van Halm VP, Peters MJ, Voskuyl AE, et al. Rheumatoid arthritis versus type 2 diabetes as a risk factor for cardiovascular disease: a cross-sectional study. Ann Rheum Dis. 2009;68(9):1395–400. DOI: 10.1136/ard.2008.094151.
11. Holmqvist ME, Wedren S, Jacobsson LT, et al. Rapid increase in myocardial infarction risk following diagnosis of rheumatoid arthritis amongst patients diagnosed between 1995 and 2006.
12. J Intern Med. 2010;268(6):578–85. DOI: 10.1111/j.1365- 2796.2010.02260.x.
13. Van Leuven SI, Franssen R, Kastelein JJ, et al. Systemic inflam- mation as a risk factor for atherothrombosis. Rheumatology (Oxford). 2008;47(1):3–7. DOI: http://dx.doi.org/10.1093/rheumatology/kem202.
14. Koopman FA, Stoof SP, Straub RH, et al. Restoring the balance of the autonomic nervous system as an innovative approach to the treatment of rheumatoid arthritis. Mol Med. 2011;17(9–10):937–48. DOI: 10.2119/molmed.2011.00065.
15. Crawford MH, Bernstein SJ, Deedwania PC, et al. ACC/AHA Guidelines for Ambulatory Electrocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the Guidelines for Ambulatory Electrocardiography). Developed in collaboration with the North American Society for Pacing and Electrophysiology. J Am Coll Cardiol. 1999;34(3):912–48. DOI: http://dx.doi.org/10.1016/S0735-1097(99)00354-X.
16. Ziegler D, Zentai CP, Perz S, et al. Prediction of mortality using measures of cardiac autonomic dysfunction in the diabetic and nondiabetic population: the MONICA/KORA Augsburg Cohort Study. Diabetes Care. 2008;31(3):556–61. DOI: http://dx.doi.org/10.2337/dc07-1615.
17. Elming H, Holm E, Jun L, et al. The prognostic value of the Q–T interval and Q–T interval dispersion in all-cause and cardiac mor- tality and morbidity in a population of Danish citizens. Eur Heart J. 1998;19(9):1391–400. DOI: http://dx.doi.org/10.1053/euhj.1998.1094.
18. Nolan J, Batin PD, Andrews N, et al. Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-Heart). Circulation. 1998;98(15):1510–6. DOI: http://dx.doi.org/10.1161/01.CIR.98.15.1510.
19. Tapanainen JM, Thomsen PE, Kober L, et al. Fractal analysis of heart rate variability and mortality after an acute myocardial infarction. Am J Cardiol. 2002:90(4):347–52. DOI: http://dx.doi.org/10.1016/S0002-9149(02)02488-8.
20. Cook S, Togni M, Schaub MC, et al. High heart rate: a cardiovas- cular risk factor? Eur Heart J. 2006;27(20):2387–93. DOI: http://dx.doi.org/10.1093/eurheartj/ehl259. Epub 2006 Sep 25.
21. Насонов ЕЛ, Каратеев ДЕ. Перспективы применения моноклональных антител к В-лимфоцитам (ритуксимаб) при ревматоидном артрите. Клиническая фармакология
22. и терапия. 2006;15(1):55–8. [Nasonov EL, Karateev DE. Perspektivy primeneniya monoklonal'nykh antitel k B-limfotsitam (rituksimab) pri revmatoidnom artrite. Klinicheskaya far- makologiya i terapiya. 2006;15(1):55–8. (In Russ.)]
23. Kerekes G, Soltesz P, Der H, et al. Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid pro- file in rheumatoid arthritis. Clin Rheumatol. 2009;28(6):705–10. DOI: 10.1007/s10067-009-1095-1.
24. Gonzalez-Juanatey C, Llorca J, Vazquez-Rodriguez TR, et al. Short-term improvement of endothelial function in rituximab- treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy. Arthritis Rheum. 2008;15;59(12):1821–4. DOI: 10.1002/art.24308.
25. Raterman HG, Levels H, Voskuyl AE, et al. HDL protein compo- sition alters from proatherogenic into less atherogenic and proin- flammatory in rheumatoid arthritis patients responding to ritux- imab. Ann Rheum Dis. 2013;72(4):560–5. DOI: 10.1136/annrheumdis-2011-201228.
26. Попкова ТВ, Новикова ДС, Линева ОГ и др. Влияние ритуксимаба на систему транспорта холестерина крови
27. у больных ревматоидным артритом. Научно-практическая ревматология. 2010;49(4):26–31. [Popkova TV, Novikova DS, Lineva OG, et al. Effect of rituximab on the blood cholesterol transport system in patientswith rheumatoid arthritis. Nauchno- prakticheskaya revmatologiya = Rheumatology Science and Practice. 2010;49(4):26–31. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2010-1162.
28. Arnett FC, Edworthy SM, Bloch DA. The ARA 1987 revised cri- teria for classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315–24. DOI: http://dx.doi.org/10.1002/art.1780310302.
29. Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford). 2003;42(2):244–57. DOI: http://dx.doi.org/10.1093/rheumatology/keg072.
30. Олюнин ЮА. Оценка активности и эффективности терапии ревматоидного артрита. В кн.: Международные индексы оценки активности, функционального статуса
31. и качества жизни больных ревматическими заболеваниями. Москва: Ассоциация ревматологов России; 2007. C. 3–12. [Olyunin YuA. Otsenka aktivnosti i effektivnosti terapii revma- toidnogo artrita. In: Mezhdunarodnye indeksy otsenki aktivnosti, funktsional'nogo statusa i kachestva zhizni bol'nykh revmaticheski- mi zabolevaniyami. [International Indices evaluate the activity, functional status and quality of life of patients with rheumatic diseases]. Moscow: Association of rheumatologists of Russia; 2007. P. 3–12.]
32. Новикова ДС, Герасимов АН, Попкова ТВ и др. Сравнение показателей вариабельности ритма сердца, нормированных по возрасту и частоте сердечных сокращений, у женщин
33. с ревматоидным артритом и женщин без ревматических заболеваний. Рациональная фармакотерапия в кардиологии. 2013;9(2):127–32. [Novikova DS, Popkova TV, Gerasimov AN, et al. Comparison of heart rate variability adjusted for age and heart rate in women with rheumatoid arthritis and women without rheumatic diseases. Ratsional'naya farmakoterapiya v kardiologii. 2013;9(2):127–32. (In Russ.)]
34. Герасимов АН. Медицинская статистика. Москва: Медицинское информационное агентство; 2007. 480 с. [Gerasimov AN. Meditsinskaya statistika [Medical statistics]. Moscow: Meditsinskoe informatsionnoe agentstvo; 2007. 480 p.]
35. Lown В, Verrier RL. Neuronal activity and ventricular fibrillation. N Engl J Med. 1976;294(21):1165–70. DOI: http://dx.doi.org/10.1056/NEJM197605202942107.
36. Bigger JT. Frequency domain measures of heart period variability and mortality rate after myocardial infarction. Circulation. 1992;85(1):164–71. DOI: http://dx.doi.org/10.1161/01.CIR.85.1.164.
37. Gwathmey JK, Warren SE, Briggs GM, et al. Diastolic dysfunc- tion in hypertrophic cardiomyopathy. Effect on active force gener- ation during systole. J Clin Invest. 1991;87(3):1023–31. DOI: http://dx.doi.org/10.1172/JCI115061.
38. Новикова ДС, Попкова ТВ, Лисицына ТА, Насонов ЕЛ. Перспективы определения вариабельности ритма сердца при ревматоидном артрите и системной красной волчанке. Вестник Российской академии медицинских наук. 2010;(9):23–34. [Novikova DS, Popkova TV, Lisitsyna TA, Nasonov EL. Prospects for the assessment of cardiac rhythm vari- ability in patients with rheumatoid arthritis and systemic lupus erythematosus. Vestnik Rossiiskoi akademii meditsinskikh nauk. 2010;(9):23–34. (In Russ.)]
39. Sajadieh A, Nielsen OW, Rasmussen V, et al. C-reactive protein, heart rate variability and prognosis in community subjects with no apparent heart disease. J Intern Med. 2006;260(4):377–87. DOI: http://dx.doi.org/10.1111/j.1365-2796.2006.01701.x.
40. Насонов ЕЛ. Проблема атеротромбоза в ревматологии. Вестник Российской академии медицинских наук. 2003;(7):6–10. [Nasonov EL. Issues related with atherothrombosis in rheumatology. Vestnik Rossiiskoi akademii meditsinskikh nauk. 2003;(7):6–10. (In Russ.)]
41. Парнес ЕЯ, Красносельский МЯ, Цурко ВВ, Cтрюк РИ. Долгосрочный прогноз у больных ревматоидным артритом
42. в зависимости от исходной вариабельности сердечного ритма. Терапевтический архив. 2005;77(9):77–80. [Parnes EYa, Krasnoselsky MYa, Tsurko VV, Stryuk RI. Long-term prognosis in patients with rheumatoid arthritis depending on baseline variability of cardiac rhythm. Terapevticheskii arkhiv. 2005;77(9):77–80. (In Russ.)]
43. Anichkov DA, Shostak NA, Ivanov DS. Heart rate variability is related to disease activity and smoking in rheumatoid arthritis patients. Int J Clin Pract. 2007;61(5):777–83. DOI: http://dx.doi.org/10.1111/j.1742-1241.2006.01099.x. Epub 2007 Mar 16.
44. Новикова ДС, Попкова ТВ, Маркелова ЕИ и др. Клиническое значение оценки вариабельности ритма сердца у больных ревматоидным артритом. Клиническая медицина. 2009;(1):27–32. [Novikova DS, Popkova TV, Markelova EI, et al. Clinical significance of the assessment of cardiac rhythm variabili- ty in patients with rheumatoid arthritis. Klinicheskaya meditsina. 2009;(1):27–32. (In Russ.)]
45. Provan SA, Semb AG, Hisdal J, et al. Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study. Ann Rheum Dis. 2010;70(5):812–7. DOI: 10.1136/ard.2010.141523.
46. Novikova DS, Popkova TV, Nasonov EL. The effect of anti-B-cell therapy on the development of atherosclerosis in patients with rheumatoid arthritis. Curr Pharm Des. 2012;18(11):1512–8. DOI: http://dx.doi.org/10.2174/138161212799504768.
47. Шальнова СА, Деев АД, Оганов РГ и др. Частота пульса и смертность от сердечно-сосудистых заболеваний
48. у российских мужчин и женщин. Результаты эпидемиологического исследования. Кардиология. 2005;45(10):45-50. [Shalnova SA, Deev AD, Oganov RG, et al. Pulse rate and cardiovascular mortality of men and women in rus- sia. the results of epidemiological studies. Kardiologiya. 2005;45(10):45-50. (In Russ.)]
49. Орлова ЯА, Макарова ГВ, Михайлов ГВ, Агеев ФТ. Снижение частоты сердечных сокращений как терапевтическая цель: фокус на первичную профилактику. Кардиоваскулярная терапия и профилактика. 2012;11(1):89–95. [Orlova YuA, Makarova GV, Mikhailova GV, Ageev FT. Heart rate reduction as a therapeutic goal: focus on pri- mary prevention. Kardiovaskulyarnaya terapiya i profilaktika. 2012;11(1):89–95. (In Russ.)]
50. Di Franco M, Paradiso M, Ceccarelli F Biological drug treatment of rheumatoid arthritis and spondyloarthritis: effects on Q–T interval and Q–T dispersion. J Rheumatol. 2012;39(1):41–5. DOI: 10.3899/jrheum.110158.
Review
For citations:
Novikova D.S., Popkova T.V., Gerasimova E.V., Novikov A.A., Aleksandrova E.N., Nasonov E.L. CHANGES IN HEART RATE, HEART RATE VARIABILITY AND QT INTERVAL IN WOMEN WITH RHEUMATOID ARTHRITIS DURING RITUXIMAB TREATMENT. Rheumatology Science and Practice. 2014;52(3):270-276. (In Russ.) https://doi.org/10.14412/1995-4484-2014-270-276
Views:
4840
Email this article 